Jalid Sehouli, MD, PhD from Charité Comprehensive Cancer Center, Berlin, Germany discusses the Phase II TRIAS 2009 trial of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian cancer (NCT01047891). According to Prof. Sehouli, this combination can increase progression-free survival (PFS) and shows an overall survival (OS) benefit compared to the standard treatment.
Recorded at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Results of TRIAS 2009 trial of sorafenib with topotecan in ovarian cancer
